Zobrazeno 1 - 10
of 154
pro vyhledávání: '"Vivien H.C. Bramwell"'
Publikováno v:
Sarcoma, Vol 8, Iss 2-3, Pp 63-69 (2004)
Purpose: Few reports have been published on the evaluation of stem cell auto transplantation for chemosensitive sarcomas. Some suggest benefit, others do not. We present results of 24 patients with sarcoma undergoing autotransplantation at a Canadian
Externí odkaz:
https://doaj.org/article/1469df1fba4444ce97dd3986703f0404
Autor:
Karama Asleh, Dongsheng Tu, Vivien H.C. Bramwell, Torsten O. Nielsen, Dongxia Gao, Lois E. Shepherd
Publikováno v:
Cancer Research. 80:P2-11
Background: Tamoxifen and aromatase inhibitors constitute the backbone of treatment for estrogen receptor positive early stage breast cancers based on immunohistochemical (IHC) results. While these therapies significantly reduce the risk of relapse o
Autor:
Dongsheng Tu, Karama Asleh, Mark Levine, Vivien H.C. Bramwell, Kathleen I. Pritchard, Dongxia Gao, Torsten O. Nielsen, Lois E. Shepherd
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(23)
Purpose: Accurate IHC biomarkers incorporating nestin positivity or inositol polyphosphate-4-phosphate (INPP4B) loss have recently been optimized to identify the basal-like intrinsic breast cancer subtype regardless of estrogen, progesterone, or Her2
Autor:
B. Dong, Mark Levine, Judy-Anne W. Chapman, Karen A. Gelmon, Wendy R. Parulekar, Lei Han, Lois E. Shepherd, R. Yerushalmi, Kathleen I. Pritchard, Margot J. Burnell, JN Ingle, Paul E. Goss, Vivien H.C. Bramwell, Michael Pollak, Keyue Ding, Timothy J. Whelan
Publikováno v:
Annals of Oncology. 28:1560-1568
Background We hypothesized that increased baseline BMI and BMI change would negatively impact clinical outcomes with adjuvant breast cancer systemic therapy. Methods Data from chemotherapy trials MA.5 and MA.21; endocrine therapy MA.12, MA.14 and MA.
Autor:
Bingshu E. Chen, Sherri R. Davies, Jeremy Hoog, Vivien H.C. Bramwell, Judy-Anne W. Chapman, Diana Ma, Lois E. Shepherd, Jingqin Luo, Matthew J. Ellis, Samuel Leung, Torsten O. Nielsen, Elaine R. Mardis
Publikováno v:
Cancer Research. 75:P4-11
Background: The copy number aberration derived endocrine response (CADER) gene signature was developed as a prognostic marker for hormone receptor positive breast cancer; it combines information derived from both gene expression and copy number aberr
Autor:
Ravi Ramjeesingh, Wendy R. Parulekar, Liting Zhu, Margot J. Burnell, Lois E. Shepherd, Vivien H.C. Bramwell, Joseph L. Pater, Bingshu E. Chen, Kathleen I. Pritchard
Publikováno v:
Cancer Research. 75:P3-09
Background: For early high risk breast cancer, adjuvant chemotherapy following definitive surgery is a current standard of care. However, the optimal time to commencement of therapy has not been well established. We evaluated the association between
Autor:
Miguel Martin, Mark Levine, Lourdes Calvo, Amparo Ruiz, Stephen Chia, Rosalia Caballero, Matthew J. Ellis, Lois E. Shepherd, Álvaro Rodríguez-Lescure, Maggie C.U. Cheang, Kathleen I. Pritchard, Vivien H.C. Bramwell, D. Voduc, Dongsheng Tu, Emilio Alba, Angelo Di Leo, Philip S. Bernard, Lisa A. Carey, Eva Carrasco, Aleix Prat, Torsten O. Nielsen, Joel S. Parker, Charles M. Perou, Manuel Ruiz-Borrego
Publikováno v:
Oncologist
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Purpose. To determine intrinsic breast cancer subtypes represented within categories defined by quantitative hormone receptor (HR) and HER2 expression. Methods. We merged 1,557 cases from three randomized phase III trials into a single data set. Thes
Autor:
H Rugo, Karen A. Gelmon, Mitch Levine, Kathleen I. Pritchard, E Vandenberg, Margot J. Burnell, E. A. Perez, Barbara Walley, Vivien H.C. Bramwell, Timothy J. Whelan, KS Albain, Lois E. Shepherd, Haji Chalchal, Judy-Anne W. Chapman, Patti O'Brien
Publikováno v:
Cancer Research. 72:P1-13
Background: In 2000, cyclophosphamide(C), epirubicin(E) and fluorouracil (F) (CEF) and doxorubicin (A) and C followed by paclitaxel (T) (AC/T) given every three weeks were commonly used regimens in Canada and the USA to treat women with node positive
Autor:
Pancras C.W. Hogendoorn, Matthew R. Sydes, Ian Lewis, Antonie H. M. Taminiau, M. Nooij, Martine Van Glabbeke, Hans Gelderblom, B. M. Uscinska, Anne McTiernan, Jeremy Whelan, Jane Hook, Vivien H.C. Bramwell, Rachel C. Jinks
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 48(5), 703-712
European Journal of Cancer, 48(5), 703-712
Aim Chemotherapy-induced toxicity is an independent prognostic indicator in several cancers. We aimed to determine whether toxicity was related to survival and histological response in high-grade localised extremity osteosarcoma. We undertook a retro
Autor:
Angel Arnaout, B. Dong, Mark Clemons, Karen A. Gelmon, T. O. Nielsen, J-Aw Chapman, Vivien H.C. Bramwell, Timothy J. Whelan, KI Pritchard, Rinat Yerushalmi, John Hilton, Nathaniel Bouganim, Frances P O'Malley, Lois E. Shepherd, Mitch Levine
Publikováno v:
Cancer Research. 71:P2-12
Background A common clinical conundrum in breast cancer management is whether pathologic T stage in women with multicentric or multifocal disease should be taken as the diameter of the largest focus or as the sum of all foci in the breast. Most stagi